Routine Assessment of Patient Index Data 3 (RAPID3) in Patients with Rheumatoid Arthritis Treated with Long-Term...

Area of Science:

• Rheumatology
• Clinical Trials
• Patient-Reported Outcomes

Background:

• The Routine Assessment of Patient Index Data 3 (RAPID3) is a validated patient-reported outcome measure for assessing rheumatoid arthritis (RA) disease activity.
• Upadacitinib is an approved treatment for RA, and its long-term efficacy is continually evaluated.

Purpose of the Study:

• To evaluate the long-term effect of upadacitinib on RAPID3 scores in patients with RA.
• To assess the proportion of patients achieving RAPID3 remission with upadacitinib treatment over 60 weeks.

Main Methods:

• Post hoc analysis of five phase 3 randomized controlled trials (RCTs) within the SELECT clinical trial program.
• Patients received upadacitinib 15 mg or 30 mg once daily, as monotherapy or with csDMARDs.
• RAPID3 remission (score ≤ 3) and correlations with CDAI, SDAI, and DAS28(CRP) were assessed at week 60.

Main Results:

• 3117 patients were included across five RCTs.
• By week 60, 32-52% of methotrexate-naïve and csDMARD-IR patients achieved RAPID3 remission with upadacitinib.
• RAPID3 scores demonstrated strong correlations with CDAI, SDAI, and DAS28(CRP) (Spearman's ρ ≥ 0.58, p < 0.001).

Conclusions:

• Upadacitinib monotherapy or combination therapy is associated with sustained patient-reported remission in RA patients over 60 weeks.
• RAPID3 is a reliable tool for assessing treatment response in RA patients receiving upadacitinib.